Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NZ-DTX Depot in advanced solid tumours
NCT04810208Phase 1Terminated
- Sponsor
- LIDDS AB
- Start
- Feb 2019
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of docetaxel in solid tumor, sponsored by LIDDS AB. Primary endpoints: Maximum tolerated dose at 5 weeks and Recommended Phase 2 dose at 5 weeks. Started Feb 2019; status: terminated.
02
Drugs
docetaxel
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04810208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04810208.